Panacea Bio receives to produce Sputnik V vaccine

The Drugs Controller General of India (DCGI) granted a licence to Panacea Biotec for manufacturing the Russian COVID-19 vaccine, Sputnik V, in India. The development comes after the first batch of the COVID-19 vaccine cleared all quality-control tests at the Gamaleya Center, Russia. Panacea Biotec, in a release on Sunday, announced that it has received a licence from the DCGI for manufacturing the Sputnik V vaccine in its Himachal Pradesh facility.

“Panacea Biotec… (is in) receipt of manufacturing licence from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund. The licence is a necessary condition for using Sputnik V produced by Panacea Biotec in India,” the pharma company said in a statement.

The Managing Director of the company, Rajesh Jain said, “Panacea Biotec is delighted to announce the obtaining of the manufacturing licence to produce Sputnik V vaccine in India. On this occasion, we thank the leadership of Prime Minister Narendra Modi and the government of India for timely hand-holding and expediting clearances to enable ‘Make in India’ vaccines.”

0

0